866-997-4948(US-Canada Toll Free)

Metastatic Brain Tumor Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Oct 2012

Category :

Oncology

No. of Pages : 39 Pages


Metastatic Brain Tumor Pipeline Review, H2 2012

Global Markets Directs, 'Metastatic Brain Tumor Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Metastatic Brain Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Metastatic Brain Tumor. Metastatic Brain Tumor Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Metastatic Brain Tumor.
  • A review of the Metastatic Brain Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Metastatic Brain Tumor pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Metastatic Brain Tumor.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Metastatic Brain Tumor pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Metastatic Brain Tumor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Metastatic Brain Tumor 7
Metastatic Brain Tumor Therapeutics under Development by Companies 9
Metastatic Brain Tumor Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Metastatic Brain Tumor Therapeutics Products under Development by Companies 14
Metastatic Brain Tumor Therapeutics Products under Investigation by Universities/Institutes 15
Companies Involved in Metastatic Brain Tumor Therapeutics Development 16
to-BBB technologies BV 16
Celtic Pharmaceutical Holdings L.P. 17
Metastatic Brain Tumor Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
corticorelin acetate - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Dendritic Cell Vaccine - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Temozolomide + Etoposide + Trofosfamid - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Sorafenib + Temozolomide - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Temozolomide + Temsirolimus - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Sorafenib + Radiation Therapy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
2B3-201 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Trental + Vitamin E - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Metastatic Brain Tumor Therapeutics Drug Profile Updates 34
Metastatic Brain Tumor Therapeutics - Dormant Products 36
Metastatic Brain Tumor Product Development Milestones 37
Featured News & Press Releases 37
Oct 03, 2011: Celtic Pharma Completes Enrollment In Dose Tolerance Trial Evaluating Xerecept In Pediatric Patients With Primary And Metastatic Brain Tumors 37

Appendix 38
Methodology 38
Coverage 38
Secondary Research 38
Primary Research 38
Expert Panel Validation 38
Contact Us 39
Disclaimer 39

List of Table


Number of Products Under Development for Metastatic Brain Tumor, H2 2012 7
Products under Development for Metastatic Brain Tumor Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
to-BBB technologies BV, H2 2012 16
Celtic Pharmaceutical Holdings L.P., H2 2012 17
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Metastatic Brain Tumor Therapeutics Drug Profile Updates 34
Metastatic Brain Tumor Therapeutics Dormant Products 36

List of Chart


Number of Products under Development for Metastatic Brain Tumor, H2 2012 7
Products under Development for Metastatic Brain Tumor Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 18
Assessment by Combination Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *